Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30850588 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNATSHRAURKARPS6KB1 | |
| SCHEMBL10645663 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNATSHRAURKAEGFR | |
| SCHEMBL17017529 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNATSHRAURKARPS6KB1 | |
| SCHEMBL22347023 | 0.78 | TSHR (0.63) | SMN1; SMN2LMNATSHRAURKARPS6KB1 | |
| 6-Benzylaminopurine SCHEMBL29772173 | 0.77 | LMNA (0.62) | SMN1; SMN2LMNATSHRAURKARPS6KB1 | |
| 6-Benzylaminopurine SCHEMBL28824679 | 0.77 | LMNA (0.62) | SMN1; SMN2LMNATSHRAURKARPS6KB1 | |
| 6-Benzylaminopurine SCHEMBL37357 | 0.77 | LMNA (0.62) | SMN1; SMN2LMNATSHRAURKARPS6KB1 | |
| SCHEMBL17009421 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNATSHRAURKARPS6KB1 | |
| SCHEMBL17017082 | 0.76 | CLK1 (0.41) | SMN1; SMN2LMNATSHREGFRMAPK1 | |
| 6-Benzylaminopurine SCHEMBL218732 | 0.75 | LMNA (0.61) | SMN1; SMN2LMNATSHRAURKARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953950-B1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200283442-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2020-09-10 | — | — | US | disclosed |
| US-10723737-B2 | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180072731-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072731-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2014124458-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072731-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | PINK1, CKMT1A; CKMT1B, NLN | SMN1; SMN2 8/4885LMNA 188/4885TSHR 4795/4885 |
| US-10723737-B2 | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | PINK1, CKMT1A; CKMT1B, NLN | SMN1; SMN2 8/4885LMNA 188/4885TSHR 4795/4885 |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | PINK1, CKMT1A; CKMT1B, NLN | SMN1; SMN2 8/4885LMNA 188/4885TSHR 4795/4885 |
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | HSP90B1, HSPBP1, HSP90AB2P | SMN1; SMN2 3538/4885LMNA 1466/4885TSHR 4478/4885 |
| US-20200283442-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | SNCA, SMN1; SMN2, CLN6 | SMN1; SMN2 2/4885LMNA 77/4885TSHR 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.